BMI-1

BMI-1 Products

  • All (5)
  • BMI-1 Inhibitors (5)
  • New BMI-1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7372 PTC-209 PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).
Front Nutr, 2023, 10:1141964
bioRxiv, 2023, 2023.01.23.525196
Int J Biol Sci, 2022, 18(7):2807-2820
S7539 PTC-209 HBr PTC-209 HBr is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
Nat Commun, 2023, 10.1038/s41467-023-42930-y
Int J Biol Sci, 2022, 18(7):2807-2820
PLoS Pathog, 2022, 18(8):e1010801
S5315 PRT4165 PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.
Nat Commun, 2023, 10.1038/s41467-023-42930-y
Leukemia, 2021, 10.1038/s41375-021-01121-8
Leukemia, 2021, 10.1038/s41375-021-01121-8
S8820 Unesbulin (PTC596) Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that accelerates BMI-1 degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis. IC50 values at 72 hours ranged from 68 to 340 nM in mantle cell lymphoma (MCL) cell lines.
NPJ Precis Oncol, 2024, 8(1):68
PLoS One, 2023, 18(2):e0277313
bioRxiv, 2023, 2023.01.23.525196
S8662 PTC-028 PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.
NPJ Precis Oncol, 2024, 8(1):68
S7372 PTC-209 PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).
Front Nutr, 2023, 10:1141964
bioRxiv, 2023, 2023.01.23.525196
Int J Biol Sci, 2022, 18(7):2807-2820
S7539 PTC-209 HBr PTC-209 HBr is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
Nat Commun, 2023, 10.1038/s41467-023-42930-y
Int J Biol Sci, 2022, 18(7):2807-2820
PLoS Pathog, 2022, 18(8):e1010801
S5315 PRT4165 PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.
Nat Commun, 2023, 10.1038/s41467-023-42930-y
Leukemia, 2021, 10.1038/s41375-021-01121-8
Leukemia, 2021, 10.1038/s41375-021-01121-8
S8820 Unesbulin (PTC596) Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that accelerates BMI-1 degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis. IC50 values at 72 hours ranged from 68 to 340 nM in mantle cell lymphoma (MCL) cell lines.
NPJ Precis Oncol, 2024, 8(1):68
PLoS One, 2023, 18(2):e0277313
bioRxiv, 2023, 2023.01.23.525196
S8662 PTC-028 PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.
NPJ Precis Oncol, 2024, 8(1):68

Choose Selective BMI-1 Inhibitors

Tags: BMI-1 inhibitor | BMI-1 modulator | BMI-1 chemical